ZyVersa Therapeutics Inc. (ZVSA)
ZyVersa Therapeutics Statistics
Share Statistics
ZyVersa Therapeutics has 2.57M shares outstanding. The number of shares has increased by 200.42% in one year.
| Shares Outstanding | 2.57M |
| Shares Change (YoY) | 200.42% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.56M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 45.48K, so 1.81% of the outstanding shares have been sold short.
| Short Interest | 45.48K |
| Short % of Shares Out | 1.81% |
| Short % of Float | 1.82% |
| Short Ratio (days to cover) | 0.19 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.29. ZyVersa Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -0.29 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ZyVersa Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15, with a Debt / Equity ratio of 0.
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -33.86 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.34B |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -6.75M |
| Effective Tax Rate | 0.07% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.68, so ZyVersa Therapeutics's price volatility has been higher than the market average.
| Beta | 0.68 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 2.11 |
| Relative Strength Index (RSI) | 27.2 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -9.14B |
| Net Income | -9.41B |
| EBITDA | -9.14B |
| EBIT | -9.15B |
| Earnings Per Share (EPS) | -848.03 |
Balance Sheet
The company has 1.53B in cash and 0 in debt, giving a net cash position of 1.53B.
| Cash & Cash Equivalents | 1.53B |
| Total Debt | 0 |
| Net Cash | 1.53B |
| Retained Earnings | -112.63B |
| Total Assets | 20.6B |
| Working Capital | -9.52B |
Cash Flow
In the last 12 months, operating cash flow was -7.56B and capital expenditures 0, giving a free cash flow of -7.56B.
| Operating Cash Flow | -7.56B |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.56B |
| FCF Per Share | -681.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZVSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ZVSA.
| Price Target | $240 |
| Price Target Difference | n/a |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Apr 26, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Apr 26, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -9.29 |
| Piotroski F-Score | 1 |